NCT05452668 2024-08-21
Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients
Children's Cancer Hospital Egypt 57357
Phase NA Unknown
Clinical Trials
834 trialsNCT06512272 2024-07-22
VOIR
Anglia Ruskin University
Phase NA Unknown
NCT05457010 2024-06-12
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Phase 1 Unknown
NCT03275493 2024-05-28
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT03560882 2024-03-21
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies
University of Kansas Medical Center
Phase 1 Unknown
NCT05536154 2024-03-19
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase NA Unknown
NCT03291444 2024-03-15
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
Phase 1 Unknown
NCT04601584 2024-03-06
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Phase 1/2 Unknown
NCT06293586 2024-03-05
Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery
Cairo University
Phase NA Unknown
NCT06285136 2024-02-29
Safety and Efficacy of Venetoclax Combination With Decitabine(DEC3-VEN) in the Treatment of AML in the Adult
The Second Affiliated Hospital of Kunming Medical University
Phase 2/3 Unknown
NCT04330820 2024-02-28
RELAX
Technische Universität Dresden
Phase 1/2 Unknown
NCT06279585 2024-02-28
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
University of Seville
Phase NA Unknown
NCT06277011 2024-02-26
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Anhui Provincial Hospital
Phase EARLY_PHASE1 Unknown
NCT06066255 2024-02-20
CASPER
Institut Paoli-Calmettes
Phase 2 Unknown
NCT04021368 2024-02-14
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA
Phase 1 Unknown
NCT04582487 2024-02-07
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase NA Unknown
NCT04731974 2024-02-07
Acute Concussion and Melatonin
Children's National Research Institute
Phase 2 Unknown
NCT05641259 2024-02-02
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1 Unknown
NCT06238336 2024-02-02
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
Shanxi Bethune Hospital
Phase 2/3 Unknown
NCT04358393 2024-02-01
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06234904 2024-01-31
Study of IBR733 Cell Injection in Acute Myeloid Leukemia
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 1 Unknown
NCT06218771 2024-01-23
A Study of TQB3454 Tablets in Patients With Blood Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT06209671 2024-01-17
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT04284228 2024-01-16
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
NexImmune Inc.
Phase 1/2 Unknown
NCT04090268 2024-01-02
SportTherapy
University of Milano Bicocca
Phase NA Unknown
NCT06177561 2023-12-20
Safety and Efficacy of LPE in Clearing DSA in Patients Who Received Allo-HSCT
Ruijin Hospital
Phase NA Unknown
NCT03236129 2023-12-18
DLI-Boost
Assistance Publique - Hôpitaux de Paris
Phase 3 Unknown
NCT04599556 2023-12-06
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
Zhejiang University
Phase 1 Unknown
NCT05925660 2023-12-05
MUCOPS
Universitaire Ziekenhuizen KU Leuven
Phase NA Unknown
NCT04663100 2023-12-04
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
University of Tennessee
Phase NA Unknown
NCT03193281 2023-11-29
KISS
University of Auckland, New Zealand
Phase 2 Unknown
NCT03614858 2023-11-29
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT03896854 2023-11-29
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT04257175 2023-11-28
CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression
Sheba Medical Center
Phase 2/3 Unknown
NCT04989335 2023-11-28
Bisantrene Combination for Resistant AML
Sheba Medical Center
Phase 2 Unknown
NCT05583175 2023-11-28
Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT05918198 2023-11-21
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Peking University People's Hospital
Phase 2 Unknown
NCT06141304 2023-11-21
Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT
The First Hospital of Jilin University
Phase 2 Unknown
NCT06134297 2023-11-18
Adherence, Viability, Clinical Evolution and Therapeutic Efficacy in Patients Undergoing Bone Marrow Transplantation
Federal University of Health Science of Porto Alegre
Phase NA Unknown
NCT06125106 2023-11-09
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
Zhejiang University
Phase 1 Unknown
NCT06087419 2023-11-02
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Unknown
NCT04767152 2023-10-30
Evaluation of Brain Changes in ALL Patients on Therapy
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase NA Unknown
NCT06105658 2023-10-30
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
Anhui Provincial Hospital
Phase 2 Unknown
NCT04964518 2023-10-25
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT05716919 2023-10-23
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Machaon Biotherapeutics, Inc.
Phase 1 Unknown
NCT05510089 2023-10-10
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase NA Unknown
NCT06073730 2023-10-10
Viale-a
The Second Affiliated Hospital of Kunming Medical University
Phase 3 Unknown
NCT06067321 2023-10-04
Gastric Residual Volumes in Infants Fed at 4 and 6 Hours Prior to General Anaesthesia
King's College Hospital NHS Trust
Phase NA Unknown
NCT04754035 2023-10-03
IMPROVE
IRCCS San Raffaele
Phase 2 Unknown
NCT04856215 2023-10-03
RITII
Great Ormond Street Hospital for Children NHS Foundation Trust
Phase 2 Unknown